Acceptability of a Fixed Combination of Fenofibrate and Metformin

Solvay Pharmaceuticals69 enrolled

Overview

The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Dyslipidemia/Glucose Metabolism Disorder

Interventions

fenofibrate and metformin fixed combination (drug)DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with type 2 diabetes mellitus and dyslipidemia. Exclusion Criteria: * Type 1 diabetes, uncontrolled type 2 diabetes, - HbA1c ≥ 10 % - Fasting plasma glucose \> 300 mg/dL - Triglycerides \> 500 mg/dL

Locations (25)

Site 24

Anzin, France

Site 23

Bachant, France

Outcomes

Primary Outcomes

Quotation by Visual Numeric Rating Scale before and after 4-week treatment

Secondary Outcomes

Assessment of safety by reporting of Adverse Events

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.